Haemonetics (HAE) Expected to Announce Quarterly Earnings on Thursday

Haemonetics (NYSE:HAE) is anticipated to issue its Q1 2027 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of $1.07 per share and revenue of $327.8930 million for the quarter. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. Interested persons may review the information on the company’s upcoming Q1 2027 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.29 EPS for the quarter, topping the consensus estimate of $1.28 by $0.01. The business had revenue of $346.35 million for the quarter, compared to analyst estimates of $336.83 million. Haemonetics had a net margin of 7.29% and a return on equity of 27.30%. The business’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.24 EPS. On average, analysts expect Haemonetics to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Haemonetics Price Performance

Shares of NYSE HAE opened at $85.63 on Thursday. The company has a current ratio of 2.95, a quick ratio of 1.87 and a debt-to-equity ratio of 1.53. The company’s 50-day moving average price is $74.25 and its 200 day moving average price is $66.05. Haemonetics has a 52 week low of $47.31 and a 52 week high of $87.32. The stock has a market cap of $3.89 billion, a price-to-earnings ratio of 42.39, a PEG ratio of 1.66 and a beta of 0.52.

Analyst Upgrades and Downgrades

Several analysts have issued reports on HAE shares. Bank of America raised shares of Haemonetics from a “neutral” rating to a “buy” rating and upped their price target for the company from $72.00 to $80.00 in a report on Friday, May 22nd. Weiss Ratings raised shares of Haemonetics from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, June 25th. Mizuho lifted their price objective on Haemonetics from $85.00 to $90.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. BTIG Research reaffirmed a “buy” rating and issued a $84.00 target price on shares of Haemonetics in a research note on Friday, June 26th. Finally, Wall Street Zen upgraded Haemonetics from a “hold” rating to a “buy” rating in a report on Saturday, May 23rd. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $78.89.

Hedge Funds Weigh In On Haemonetics

A number of hedge funds have recently made changes to their positions in the stock. Sivia Capital Partners LLC acquired a new stake in shares of Haemonetics during the 2nd quarter worth $234,000. O Shaughnessy Asset Management LLC acquired a new position in Haemonetics in the fourth quarter valued at $242,000. Amundi acquired a new position in Haemonetics in the fourth quarter valued at $222,000. State of Wyoming acquired a new position in Haemonetics in the fourth quarter valued at $220,000. Finally, Strs Ohio purchased a new stake in Haemonetics during the first quarter valued at about $140,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.